Hypoadiponectinaemia in diabetes mellitus type 2: Molecular mechanisms and clinical significance

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 12, 2011, Pages 897-904

  Su, Hui ^a,b   Lau, Wayne Bond ^b   Ma, Xin Liang ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adiponectin; Gene regulation; Hypoadiponectinaemia; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INTERLEUKIN 18; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RECOMBINANT CYTOKINE; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY RISK; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENERGY BALANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPOADIPONECTINEMIA; HYPOXEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OLIGOMERIZATION; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN PROCESSING; REPERFUSION INJURY; REVIEW; TRANSCRIPTION REGULATION; WEIGHT REDUCTION;

ADIPONECTIN; ANIMALS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICE; OBESITY; PROMOTER REGIONS, GENETIC; RATS; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 82355170610     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05606.x     Document Type: Review

References (67)

1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995; 270: 26746-9.
2. Wang Y, Lau WB, Gao E et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am. J. Physiol. Endocrinol. Metab. 2009; 298: E663-70.
3. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 1998; 8: 335-8.
4. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin Implications fpr metabolic regulation and bioactivity. J. Biol. Chem. 2003; 278: 9073-85.
5. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001; 7: 947-53.
6. Li R, Wang WQ, Zhang H et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am. J. Physiol. Endocrinol. Metab. 2007; 293: E1703-8.
7. Tao L, Gao E, Jiao X et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115: 1408-16.
8. Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005; 11: 1096-103.
9. Das K, Lin Y, Widen E, Zhang Y, Scherer PE. Chromosomal localization, expression pattern, and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30. Biochem. Biophys. Res. Commun. 2001; 280: 1120-9.
10. Takahashi M, Arita Y, Yamagata K et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int. J. Obes. Relat. Metab. Disord. 2000; 24: 861-8.
11. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-63.
12. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-74.
13. He W, Barak Y, Hevener A et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA 2003; 100: 15712-7.
14. Seo JB, Moon HM, Noh MJ et al. Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J. Biol. Chem. 2004; 279: 22108-17.
15. Doran AC, Meller N, Cutchins A et al. The helix-loop-helix factors Id3 and E47 are novel regulators of adiponectin. Circ. Res. 2008; 103: 624-34.
16. Qiao L, Maclean PS, Schaack J et al. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 2005; 54: 1744-54.
17. Nakae J, Kitamura T, Kitamura Y, Biggs WH III, Arden KC, Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev. Cell. 2003; 4: 119-29.
18. Banks AS, Kon N, Knight C et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008; 8: 333-41.
19. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J. Biol. Chem. 2006; 281: 39915-24.
20. Qi L, Saberi M, Zmuda E et al. Adipocyte CREB promotes insulin resistance in obesity. Cell Metab. 2009; 9: 277-86.
21. Zhang JW, Klemm DJ, Vinson C, Lane MD. Role of CREB in transcriptional regulation of CCAAT/enhancer-binding protein beta gene during adipogenesis. J. Biol. Chem. 2004; 279: 4471-8.
22. Kim HB, Kong M, Kim TM et al. NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. Diabetes 2006; 55: 1342-52.
23. Liu B, Lee HY, Weinzimer SA et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J. Biol. Chem. 2000; 275: 33607-13.
24. Zappala G, Rechler MM. IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochem. Biophys. Res. Commun. 2009; 382: 785-9.
25. Aso Y, Yamamoto R, Wakabayashi S et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006; 55: 1954-60.
26. Fisher FF, Trujillo ME, Hanif W et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia. 2005; 48: 1084-7.
27. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J. 2008; 409: 623-33.
28. Wang Y, Lam KS, Chan L et al. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J. Biol. Chem. 2006; 281: 16391-400.
29. Richards AA, Stephens T, Charlton HK et al. Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol. Endocrinol. 2006; 20: 1673-87.
30. Waki H, Yamauchi T, Kamon J et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J. Biol. Chem. 2003; 278: 40352-63.
31. Wang ZV, Scherer PE. DsbA-L is a versatile player in adiponectin secretion. Proc. Natl. Acad. Sci. USA 2008; 105: 18077-8.
32. Phillips SA, Kung J, Ciaraldi TP et al. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am. J. Physiol. Endocrinol. Metab. 2009; 297: E767-73.
33. Long Q, Lei T, Feng B et al. Peroxisome proliferator-activated receptor-gamma increases adiponectin secretion via transcriptional repression of endoplasmic reticulum chaperone protein ERp44. Endocrinology 2010; 151: 3195-203.
34. Wang A, Liu M, Liu X et al. Up-regulation of adiponectin by resveratrol: The essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L. J. Biol. Chem. 2010; 286: 60-6.
35. Liu M, Zhou L, Xu A et al. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc. Natl. Acad. Sci. USA 2008; 105: 18302-7.
36. Zhou L, Liu M, Zhang J, Chen H, Dong LQ, Liu F. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulation. Diabetes 2010; 59: 2809-16.
37. Banga A, Unal R, Tripathi P et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am. J. Physiol. Endocrinol. Metab. 2009; 296: E480-9.
38. Qiang L, Wang H, Farmer SR. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol. Cell. Biol. 2007; 27: 4698-707.
39. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia. 2003; 46: 459-69.
40. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004; 279: 12152-62.
41. Mazzali G, Di Francesco V, Zoico E et al. Interrelations between fat distribution, muscle lipid content, adipocytokines, and insulin resistance: Effect of moderate weight loss in older women. Am. J. Clin. Nutr. 2006; 84: 1193-9.
42. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J. Am. Coll. Cardiol. 2006; 48: 1369-77.
43. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-33.
44. Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-8.
45. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-85.
46. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 2003; 26: 3226-9.
47. Knobler H, Benderly M, Boyko V et al. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. Eur. J. Endocrinol. 2006; 154: 87-92.
48. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-9.
49. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 85-9.
50. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: A population-based 10-year follow-up study in elderly men. J. Clin. Endocrinol. Metab. 2007; 92: 571-6.
51. Shibata R, Numaguchi Y, Matsushita K et al. Usefulness of adiponectin to predict myocardial salvage following successful reperfusion in patients with acute myocardial infarction. Am. J. Cardiol. 2008; 101: 1712-5.
52. Iwashima Y, Katsuya T, Ishikawa K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-23.
53. Gregor MF, Hotamisligil GS. Thematic review series: adipocyte biology. Adipocyte stress: The endoplasmic reticulum and metabolic disease. J. Lipid Res. 2007; 48: 1905-14.
54. Zhou L, Liu F. Autophagy: roles in obesity-induced ER stress and adiponectin downregulation in adipocytes. Autophagy 2010; 6: 1196-7.
55. Hosogai N, Fukuhara A, Oshima K et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-11.
56. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2002; 290: 1084-9.
57. Kim HS, Ali O, Shim M et al. Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr. Res. 2007; 61: 159-64.
58. Kim KY, Kim JK, Jeon JH, Yoon SR, Choi I, Yang Y. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2005; 327: 460-7.
59. Kamon J, Yamauchi T, Muto S et al. A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem. Biophys. Res. Commun. 2004; 323: 242-8.
60. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 2001; 507: 142-6.
61. Degawa-Yamauchi M, Moss KA, Bovenkerk JE et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes. Res. 2005; 13: 662-9.
62. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2004; 89: 4312-9.
63. Combs TP, Wagner JA, Berger J et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
64. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9.
65. Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem. Biophys. Res. Commun. 2004; 314: 151-8.
66. Liu HR, Tao L, Gao E et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc. Res. 2004; 62: 135-44.
67. Tao L, Wang Y, Gao E et al. Adiponectin: An indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ. Res. 2010; 106: 409-17.